- Service Name
DURECT Corporation
- Industry
Pharmaceutical, Specialty Pharmaceuticals, Epigenetics, Therapeutics
- Main Value Proposition
DURECT offers a unique approach to treating serious medical conditions by harnessing the power of epigenetic modulation, potentially changing the course of diseases and improving patient outcomes.
- Description
DURECT Corporation is a specialty pharmaceutical company focused on developing innovative epigenetic therapeutics. Their primary aim is to treat serious conditions such as acute organ injury and cancer through epigenetic modulation.
- Key Features
Targeting dysregulated DNA methylation; Potential to treat acute organ injuries and cancers; Clinical trials demonstrating efficacy in Alcohol-Associated Hepatitis; Strategic partnerships to enhance therapeutic options
- Use Cases
DURECT's therapies are most valuable in treating acute organ injuries, cancers, and conditions like Alcohol-Associated Hepatitis, where traditional treatments may fall short.
- Competitive advantages
Innovative focus on epigenetic therapies; Strong clinical trial results, particularly in Alcohol-Associated Hepatitis; Potential to establish new standards of care in serious conditions
- Strengths
DURECT's strengths lie in its innovative research, strong clinical trial results, and a dedicated team focused on advancing epigenetic therapies.
- Positioning
DURECT positions itself as a leader in the emerging field of epigenetic therapeutics, aiming to revolutionize treatment for serious medical conditions.
- Audience
The target users include healthcare professionals, patients suffering from serious conditions, and potential investors interested in innovative pharmaceutical solutions.
- CTA
Discover DURECT
- Tags
epigenetic therapeutics
clinical trials
acute organ injury
cancer treatment
- Tagline
Unlocking the potential of epigenetic therapeutics to revolutionize medicine
- Tone of Voice
Innovative, compassionate, authoritative
- Differentiation
DURECT's focus on epigenetic modulation sets it apart from traditional pharmaceutical approaches, as it targets the underlying epigenomic dysregulation rather than just the symptoms of diseases.
- Brand Positioning
DURECT's brand identity is centered around innovation, patient care, and the potential to transform medical treatment through cutting-edge science.
- Founded
1998-01-01
- Founders
James E. Brown